Heron Therapeutics, Inc.
HRTX
$1.10
$0.000.00%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -634.78% | -190.36% | -28.06% | 175.56% | 47.50% |
| Total Depreciation and Amortization | 0.65% | 10.89% | -5.16% | 0.00% | -9.36% |
| Total Amortization of Deferred Charges | -4.85% | -2.37% | -29.67% | -20.42% | 161.81% |
| Total Other Non-Cash Items | 434.98% | 22.36% | 8.77% | -32.86% | -58.63% |
| Change in Net Operating Assets | 130.36% | 17.09% | 21.15% | -531.19% | 224.31% |
| Cash from Operations | 112.25% | -22.53% | 24.70% | -449.45% | 173.22% |
| Capital Expenditure | 100.00% | -90.83% | 82.92% | -48.03% | 32.34% |
| Sale of Property, Plant, and Equipment | 163.64% | -73.81% | 55.56% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 57.07% | 221.84% | -80.55% | 173.32% | 63.91% |
| Cash from Investing | 61.69% | 222.66% | -80.09% | 187.61% | 93.85% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 3,314.82% | -- | -- | 23.68% | 95.43% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -3,492.27% | 203.13% | -- | -- | -203.47% |
| Cash from Financing | 1,611.01% | 1,120.31% | -84.87% | 2,921.43% | -97.15% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,064.48% | 57.86% | -10,809.84% | -99.17% | 456.35% |